Literature DB >> 7783761

Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders.

Z Argov1, Y Shapira, L Averbuch-Heller, I Wirguin.   

Abstract

LEMS is a presynaptic neuromuscular junction disorder typically associated with small cell lung carcinoma. The characteristic electrophysiological abnormality is a low amplitude compound muscle action potential that shows a marked increment after short maximal contraction or brief tetanic nerve stimulation. Here we describe 3 patients who had LEMS in association with lymphoproliferative disorder. The first patient had Castleman's syndrome with typical clinical and electrophysiological features of LEMS, which responded partially to treatment with 3-4-diaminopyridine. The second patient was a 7-year-old boy who had an unusual acute onset of LEMS associated with relapse of his Burkitt's leukemia. The third patient was a 60-year-old woman with non-Hodgkin's lymphoma. These 3 patients (together with 6 additional patients identified in the literature) lead us to suggest that lymphoproliferative diseases are another, hitherto unrecognized, type of malignancy associated with LEMS. Thus, any patient with these malignancies and unexplained muscle weakness should have electrophysiological evaluation for LEMS.

Entities:  

Mesh:

Year:  1995        PMID: 7783761     DOI: 10.1002/mus.880180707

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

Review 1.  Neurologic complications of non-Hodgkin's lymphoma.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 2.  Neurologic complications of non-Hodgkin's lymphoma.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 3.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

Review 4.  Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.

Authors:  Benedikt Schoser; Bruno Eymard; Joe Datt; Renato Mantegazza
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

5.  Lambert-eaton myasthenic syndrome.

Authors:  Maria B Weimer; Joaquin Wong
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

6.  Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.

Authors:  P Maddison; B Lang; K Mills; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

Review 7.  Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas.

Authors:  Francesc Graus; Helena Ariño; Josep Dalmau
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

8.  Large granular lymphocytic leukemia associated with Lambert-Eaton Myasthenic Syndrome: A case report.

Authors:  Richard Lemal; Carine Chaleteix; Patrice Minard; Corinne Roche; Jacques-Olivier Bay; Olivier Tournilhac; Thierry Lamy
Journal:  Leuk Res Rep       Date:  2013-04-02

9.  Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.

Authors:  Simona Portaro; Teresa Brizzi; Stefano Sinicropi; Alberto Cacciola; Maria Cristina De Cola; Alessia Bramanti; Demetrio Milardi; Antonino Lupica; Placido Bramanti; Antonio Toscano; Carmelo Rodolico
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.